Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Reversal: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| Epigenetic Modifications | associated_with | process | 0.95 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli | 0.937 | neurodegeneration | TREM2 in Alzheimer's Disease: Mechanisms |
| SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc | 0.893 | neurodegeneration | Gene expression changes in aging mouse b |
| NLRP3 Inhibition (H7): Downstream Inflammatory Reversal | 0.780 | neurodegeneration | Does restoring neuronal AMPK activity re |
| Glymphatic System-Enhanced Antibody Clearance Reversal | 0.537 | neurodegeneration | Blood-brain barrier transport mechanisms |
| CX3CR1-Targeted AntimiR-155 Oligonucleotides for Microglial | 0.530 | pharmacology | How can CNS-selective HDAC/DNMT inhibito |
| CSF1R Inhibition Reversal Window Depends on Microglia Replac | 0.395 | neurodegeneration | What is the optimal therapeutic window f |
| NAD+-SIRT1-H3K9me3 restoration enables true senescence rever | 0.000 | Alzheimer's disease | Can metabolic interventions truly revers |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multi [PMID:40773034] | Leitner U, Chew SH, Blanch J, Viswanatha | J Neurol | 2025 | 1 |
| B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum [PMID:39222408] | Bennett JL, Pittock SJ, Paul F, Kim HJ, | Ann Clin Transl Neurol | 2024 | 1 |
| Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic str [PMID:34530847] | Carnero Contentti E, Correale J | J Neuroinflammation | 2021 | 1 |
| Ganglion Cell Layer Compared With Inner Plexiform Layer Atrophy After Optic Neur [PMID:41881459] | Filippatou AG, Gakis G, Bacchetti A, Kim | Neurology(R) neuroimmunology & | 2026 | 0 |
| β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral ed [PMID:41535708] | Yu MJ, Xiong RQ, Wu JW, Li YC, Xie JX et | Acta Pharmacol Sin | 2026 | 0 |
| CCR2 knockdown attenuates post-hemorrhagic hydrocephalus and improves glymphatic [PMID:41539459] | Deng H, Zhang S, Wang H, Liu X, Zhong K | Exp Neurol | 2026 | 0 |
| Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis opt [PMID:41665955] | Qi F, Lennon VA, Zhao S, Guo Y, Ding H e | J Clin Invest | 2026 | 0 |
| Safety and efficacy of ravulizumab in patients with NMOSD previously treated wit [PMID:41782198] | Bennett JL, Bhattacharyya S, Zabeti A, L | Mult Scler | 2026 | 0 |
| NMOSD and MOGAD: Updates on diagnostic criteria. [PMID:41927386] | Marignier R, Leal Rato M | Rev Neurol (Paris) | 2026 | 0 |
| Therapeutic updates in NMOSD and MOGAD: From present practice to future promise. [PMID:41927387] | Elosua-Bayés I, Cobo-Calvo A | Rev Neurol (Paris) | 2026 | 0 |
| Recurrent aquaporin 4-immunoglobulin G-positive neuromyelitis optica spectrum di [PMID:41915816] | Jiang X, Chen J, Wen Y, Yuan L, Zhang J | The Journal of international m | 2026 | 0 |
| Glymphatic System Dysfunction in Central Nervous System Diseases. [PMID:41792880] | Zahran A, Abu-Khazneh O, Bdair M, Hajjeh | CNS neuroscience & therapeutic | 2026 | 0 |
| Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD [PMID:41921124] | Tournier A, Gavoille A, Pique J, Levraut | Neurology | 2026 | 0 |
| Mapping the Brain's Glymphatic System. [PMID:41751308] | Voumvourakis K, Thomaidis NS, Tsiodras S | Biomedicines | 2026 | 0 |
| Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling [PMID:41843863] | Deschamps R, Papeix C, Demortiere S, Lar | Neurology | 2026 | 0 |
| A compound pulsed magnetic field achieves superior cognitive benefits against Al [PMID:41856031] | Wang X, Wang X, Zhao H, Zhao C, Wang P, | Neurotherapeutics : the journa | 2026 | 0 |
| Physical exercise as a non-pharmacological strategy to enhance glymphatic functi [PMID:41676384] | Ghayourvahdat A, Azimizonuzi H, Ahmed M | IBRO neuroscience reports | 2026 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkins [PMID:39964974] | Dai L, Wang J, Meng L, Zhang X, Xiao T, | PLoS biology | 2025 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning Reversal in their description or question text
Score: 0.395 · neurodegeneration · 2026-04-22
## Mechanistic Overview CSF1R Inhibition Reversal Window Depends on Microglia Replacement Kinetics starts from the claim
Score: 0.000 · Alzheimer's disease · 2026-04-26
Partial metabolic interventions (e.g., mTOR inhibition alone) suppress SASP secretion but leave growth arrest intact bec